Corcept Therapeutics (CORT)
(Delayed Data from NSDQ)
$31.56 USD
-1.11 (-3.40%)
Updated Jul 2, 2024 04:00 PM ET
After-Market: $31.53 -0.03 (-0.10%) 7:58 PM ET
1-Strong Buy of 5 1
D Value C Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CORT 31.56 -1.11(-3.40%)
Will CORT be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CORT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CORT
Corcept (CORT) Shares Rise 20% in Three Months: Here's Why
Corcept Therapeutics (CORT) is a Top-Ranked Momentum Stock: Should You Buy?
CORT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Corcept Therapeutics (CORT) is a Top-Ranked Momentum Stock: Should You Buy?
Why Is Pacira (PCRX) Up 1.7% Since Last Earnings Report?
Corcept (CORT) Up 24.5% Since Last Earnings Report: Can It Continue?
Other News for CORT
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024
7 Biotech Stocks to Boost Your Portfolio to Peak Health
Interesting CORT Put And Call Options For February 2025
Corcept Therapeutics (CORT) Gets a Buy from Truist Financial
Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific Sessions